231 related articles for article (PubMed ID: 21298375)
1. Targeted therapies for metastatic esophagogastric cancer.
Reddy D; Wainberg ZA
Curr Treat Options Oncol; 2011 Mar; 12(1):46-60. PubMed ID: 21298375
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
3. HER2 directed therapy for gastric/esophageal cancers.
Won E; Janjigian YJ; Ilson DH
Curr Treat Options Oncol; 2014 Sep; 15(3):395-404. PubMed ID: 24811128
[TBL] [Abstract][Full Text] [Related]
4. Esophagogastric cancer: integration of targeted therapies into systemic chemotherapy.
Moehler M; Schwarz S; Wagner AD
Curr Cancer Drug Targets; 2011 Jul; 11(6):681-7. PubMed ID: 21651462
[TBL] [Abstract][Full Text] [Related]
5. Esophagogastric cancer: targeted agents.
Ku GY; Ilson DH
Cancer Treat Rev; 2010 May; 36(3):235-48. PubMed ID: 20122806
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies with chemoradiation in esophageal cancer: development and future directions.
Hong TS; Wo JY; Kwak EL
Semin Radiat Oncol; 2013 Jan; 23(1):31-7. PubMed ID: 23207045
[TBL] [Abstract][Full Text] [Related]
7. Emerging mAbs for the treatment of esophagogastric cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2015 Mar; 20(1):63-74. PubMed ID: 25483267
[TBL] [Abstract][Full Text] [Related]
8. Impact of genetic targets on cancer therapy in esophagogastric cancer.
Jiang Y
Adv Exp Med Biol; 2013; 779():55-65. PubMed ID: 23288635
[TBL] [Abstract][Full Text] [Related]
9. Targeting the human EGFR family in esophagogastric cancer.
Okines A; Cunningham D; Chau I
Nat Rev Clin Oncol; 2011 Apr; 8(8):492-503. PubMed ID: 21468131
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for esophagogastric cancer: targeted therapies.
Lyons TG; Ku GY
Chin Clin Oncol; 2017 Oct; 6(5):48. PubMed ID: 29129088
[TBL] [Abstract][Full Text] [Related]
11. Targeted Treatment of Esophagogastric Cancer.
Kopp HG; Hofheinz RD
Oncol Res Treat; 2016; 39(12):788-794. PubMed ID: 27889780
[TBL] [Abstract][Full Text] [Related]
12. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
13. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.
Chaudhary SP; Kwak EL; Hwang KL; Lennerz JK; Corcoran RB; Heist RS; Russo AL; Parikh A; Borger DR; Blaszkowsky LS; Faris JE; Murphy JE; Azzoli CG; Roeland EJ; Goyal L; Allen J; Mullen JT; Ryan DP; Iafrate AJ; Klempner SJ; Clark JW; Hong TS
Oncologist; 2020 Nov; 25(11):e1691-e1700. PubMed ID: 32820577
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract][Full Text] [Related]
15. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
16. Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer.
Mamdani H; Jalal SI
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-16. PubMed ID: 33770461
[TBL] [Abstract][Full Text] [Related]
17. Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval.
Gencer D; Al-Batran SE; Dada R; Hünerlitürkoglu AN; Gonnermann M; Kegel T; Scheiber H; Jordan WO; Burkholder I; Kellermann L; Hofheinz RD
J Cancer Res Clin Oncol; 2013 Feb; 139(2):337-45. PubMed ID: 23080134
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Ayyappan S; Prabhakar D; Sharma N
Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Moehler M; Mahlberg R; Heinemann V; Obermannová R; Kubala E; Melichar B; Weinmann A; Scigalla P; Tesařová M; Janda P; Hédouin-Biville F; Mansoor W
Gastric Cancer; 2017 Mar; 20(2):358-367. PubMed ID: 27255289
[TBL] [Abstract][Full Text] [Related]
20. HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers.
Cytryn SL; Janjigian YY
J Natl Compr Canc Netw; 2023 Apr; 21(4):423-429. PubMed ID: 37015333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
